Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

968 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y, Kawanami D. Muta Y, et al. Among authors: tsukamoto s. Front Pharmacol. 2024 Mar 27;15:1358573. doi: 10.3389/fphar.2024.1358573. eCollection 2024. Front Pharmacol. 2024. PMID: 38601470 Free PMC article.
Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Tsukamoto S, Urate S, Yamada T, Azushima K, Yamaji T, Kinguchi S, Uneda K, Kanaoka T, Wakui H, Tamura K. Tsukamoto S, et al. Front Pharmacol. 2022 May 18;13:885457. doi: 10.3389/fphar.2022.885457. eCollection 2022. Front Pharmacol. 2022. PMID: 35662736 Free PMC article.
Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Tsukamoto S, Morita R, Yamada T, Urate S, Azushima K, Uneda K, Kobayashi R, Kanaoka T, Wakui H, Tamura K. Tsukamoto S, et al. Diabetes Res Clin Pract. 2022 Dec;194:110161. doi: 10.1016/j.diabres.2022.110161. Epub 2022 Nov 17. Diabetes Res Clin Pract. 2022. PMID: 36403681
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
Kobayashi K, Toyoda M, Hatori N, Tsukamoto S, Kimura M, Sakai H, Furuki T, Chin K, Kanaoka T, Aoyama T, Umezono T, Ito S, Suzuki D, Takeda H, Degawa H, Hishiki T, Shimura H, Nakajima S, Miyauchi M, Yamamoto H, Hatori Y, Hayashi M, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: tsukamoto s. Cardiovasc Endocrinol Metab. 2023 Sep 28;12(4):e0292. doi: 10.1097/XCE.0000000000000292. eCollection 2023 Dec. Cardiovasc Endocrinol Metab. 2023. PMID: 37779602 Free PMC article.
Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.
Tsukamoto S, Kobayashi K, Toyoda M, Hatori N, Kanaoka T, Wakui H, Sakai H, Furuki T, Chin K, Ito S, Suzuki D, Umezono T, Aoyama T, Nakajima S, Hishiki T, Hatori Y, Hayashi M, Shimura H, Minagawa F, Mokubo A, Takihata M, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Tsukamoto S, et al. Hypertens Res. 2024 Mar;47(3):628-638. doi: 10.1038/s41440-023-01464-y. Epub 2023 Oct 17. Hypertens Res. 2024. PMID: 37848562
968 results